Amended Statement of Ownership: Solicitation (sc 14d9/a)
16 September 2017 - 6:52AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
14D-9
(Rule 14d-101)
(Amendment No. 3)
SOLICITATION/RECOMMENDATION STATEMENT
UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934
Kite Pharma, Inc.
(Name
of Subject Company)
Kite Pharma, Inc.
(Name
of Person Filing Statement)
COMMON STOCK, PAR VALUE $0.001 PER SHARE
(Title of Class of Securities)
49803L109
(CUSIP Number
of Class of Securities)
Arie Belldegrun, M.D.
President and Chief Executive Officer
Kite Pharma, Inc.
2225
Colorado Avenue
Santa Monica, California 90404
(310) 824-9999
(Name,
address and telephone numbers of person authorized to receive notices and communications
on behalf of the persons filing statement)
With copies to:
Alison S. Ressler
Eric
M. Krautheimer
Sullivan & Cromwell LLP
1888 Century Park East
Los Angeles, California 90067
(310) 712-6600
☐
|
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
This Amendment No. 3 (this
Amendment
) to Schedule 14D-9 amends and
supplements the Schedule 14D-9 previously filed by Kite Pharma, Inc., a Delaware corporation (the
Company
) with the U.S. Securities and Exchange Commission on September 5, 2017, and amended on September 7, 2017 and
September 8, 2017 (as amended, the
Solicitation/Recommendation Statement
), with respect to the tender offer by Dodgers Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead Sciences, Inc., a
Delaware corporation, to purchase all outstanding shares of the Companys common stock, par value $0.001 per share. The information set forth in the Solicitation/Recommendation Statement remains unchanged and is incorporated herein by
reference, except that such information is hereby amended or supplemented to the extent specifically provided herein.
Item 9 of the Solicitation/Recommendation Statement is hereby amended and supplemented
by adding the following exhibits:
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and
correct.
|
|
|
|
|
|
|
|
|
|
|
|
|
KITE PHARMA, INC.
|
|
|
|
|
Dated: September 15, 2017
|
|
|
|
By:
|
|
/s/ Arie Belldegrun
|
|
|
|
|
|
|
Name:
|
|
Arie Belldegrun, M.D.
|
|
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Dec 2024 to Jan 2025
KITE PHARMA, INC. (NASDAQ:KITE)
Historical Stock Chart
From Jan 2024 to Jan 2025